TNFSF4 and pulmonary arterial hypertension: Interference of OX40-OX40L signaling presents as an attractive avenue of potential prophylaxis and/or therapy for a variety of fibrotic diseases including systemic sclerosis, pulmonary arterial hypertension, dermal fibrosis, and atherosclerosis.